Bezu Lucillia, Gomes-de-Silva Ligia C, Dewitte Heleen, Breckpot Karine, Fucikova Jitka, Spisek Radek, Galluzzi Lorenzo, Kepp Oliver, Kroemer Guido
Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers , Paris , France ; U1138, INSERM , Paris , France ; Metabolomics and Cell Biology Platforms, Gustave Roussy Campus Cancer , Villejuif , France ; Faculté de Medecine, Université Paris-Sud , Le Kremlin-Bicêtre , France.
Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers , Paris , France ; U1138, INSERM , Paris , France ; Metabolomics and Cell Biology Platforms, Gustave Roussy Campus Cancer , Villejuif , France ; Department of Chemistry, University of Coimbra , Coimbra , Portugal.
Front Immunol. 2015 Apr 24;6:187. doi: 10.3389/fimmu.2015.00187. eCollection 2015.
The term "immunogenic cell death" (ICD) is commonly employed to indicate a peculiar instance of regulated cell death (RCD) that engages the adaptive arm of the immune system. The inoculation of cancer cells undergoing ICD into immunocompetent animals elicits a specific immune response associated with the establishment of immunological memory. Only a few agents are intrinsically endowed with the ability to trigger ICD. These include a few chemotherapeutics that are routinely employed in the clinic, like doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well as some agents that have not yet been approved for use in humans. Accumulating clinical data indicate that the activation of adaptive immune responses against dying cancer cells is associated with improved disease outcome in patients affected by various neoplasms. Thus, novel therapeutic regimens that trigger ICD are urgently awaited. Here, we discuss current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD.
术语“免疫原性细胞死亡”（ICD）通常用于表示一种特殊的程序性细胞死亡（RCD）情况，它涉及免疫系统的适应性分支。将经历ICD的癌细胞接种到具有免疫活性的动物体内会引发与免疫记忆建立相关的特异性免疫反应。只有少数几种物质本质上具有触发ICD的能力。这些物质包括临床上常规使用的一些化疗药物，如阿霉素、米托蒽醌、奥沙利铂和环磷酰胺，以及一些尚未被批准用于人类的物质。越来越多的临床数据表明，针对垂死癌细胞的适应性免疫反应的激活与受各种肿瘤影响的患者疾病预后的改善有关。因此，迫切需要能够触发ICD的新型治疗方案。在此，我们讨论当前将原本无免疫原性的RCD实例转化为真正ICD的联合方法。
